CME in Minutes: Education in Dermatology

49 Episodes

Reverse

Nikhil I. Khushalani, MD - From Trial to Team: Optimizing Adjuvant Immunotherapy for High-Risk Cutaneous Squamous Cell Carcinoma

2025-09-2215:59

Please visit answersincme.com/860/TSG to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses evidence-based insights that inform the practical integration of adjuvant immunotherapy regimens into cutaneous squamous cell carcinoma (CSCC) care, based on available clinical data. Upon completion of this activity, participants should be better able to: Review the rationale for immunotherapy in the adjuvant treatment of patients with high-risk resected cutaneous squamous cell carcinoma (CSCC); Summarize the latest clinical trial data evaluating adjuvant immunotherapy in high-risk CSCC; and Outline evidence-based, multidisciplinary strategies to optimize the care of patients with high-risk CSCC in the adjuvant setting.

April W. Armstrong, MD, MPH / Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Next-Generation Treatments for Moderate-to-Severe Plaque Psoriasis: What's New in TYK2

2025-08-0455:28

Please visit answersincme.com/JCY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the current and potential clinical impact of TYK2 inhibitors. Upon completion of this activity, participants should be better able to: Contrast the clinical implications of selective TYK2 inhibition versus pan-JAK inhibition in the treatment of moderate-to-severe plaque psoriasis; Interpret the clinical evidence for next-generation TYK2 inhibitors in patients with moderate-to-severe plaque psoriasis; and Integrate TYK2 inhibitors into clinical practice as they become available for patients with moderate-to-severe plaque psoriasis.

Neil D. Gross, MD, FACS - Evolving the Multi-Modal Approach for Resectable Cutaneous Squamous Cell Carcinoma: A Multidisciplinary Assessment of Current and Emerging Immunotherapeutic Strategies

2025-07-1101:09:29

Please visit answersincme.com/VJW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in cutaneous oncology discuss the role of emerging immunotherapeutic strategies in treating resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Review the current guideline-recommended use of immunotherapies for the management of resectable CSCC; Identify clinical factors that will guide the use of immunotherapeutic approaches for patients with resectable CSCC; Outline proactive strategies to enhance the benefit-to-risk profile of immunotherapy for patients with resectable CSCC; and Describe the evolving role of novel applications of immunotherapy in the treatment of resectable CSCC. This activity is intended for US healthcare professionals only.

Hussein Tawbi, MD, PhD - Evolving Melanoma Care: The Clinical Impact of Anti-LAG-3/PD-1 Combinations

2025-07-0723:00

Please visit answersincme.com/XWB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses combination anti–programmed cell death protein 1 (PD-1) plus anti–lymphocyte-activation gene 3 (LAG-3) therapy. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence supporting use of combination anti–PD-1 plus anti-LAG-3 therapy in the first-line setting for patients with unresectable, advanced melanoma; Identify eligible patients with unresectable, advanced melanoma who can benefit from the use of combination anti–PD-1 plus anti–LAG-3 therapy in the first-line setting; and Outline strategies for managing adverse events associated with combination anti–PD-1 plus anti–LAG-3 therapy.

Emma Guttman-Yassky, MD, PhD - Taking a New Approach to Relieving Atopic Dermatitis: The Evidence for OX40/OX40L Therapies

2025-05-2915:06

Please visit answersincme.com/CKC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the evolving role of OX40/OX40L-targeted monoclonal antibodies (mAbs) for the treatment of moderate to severe atopic dermatitis.Upon completion of this activity, participants should be better able to: Recognize the rationale for targeting OX40/OX40L in the treatment of moderate to severe atopic dermatitis (AD); Review the clinical profiles of OX40/OX40L-targeted monoclonal antibodies in treating moderate to severe AD; and Outline clinical considerations for the future integration of OX40/OX40L-targeted mAbs into treatment plans for moderate to severe AD.

Nathan Falk, MD, MBA, FAAFP - Making Sense of Type 2 Inflammation Crosstalk in Chronic Diseases: Perspectives on Improving Emergency and Primary Care Collaboration

2025-04-0216:48

Please visit answersincme.com/SFM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in family and emergency medicine discuss collaborative strategies for the optimal management of type 2 inflammatory diseases. Upon completion of this activity, participants should be better able to: Specify how type 2 inflammation contributes to the pathophysiology of chronic type 2 inflammatory diseases; Recognize the cardinal signs and symptoms of diseases presenting with type 2 inflammation; Apply treatment considerations for patients with multiple type 2 inflammatory diseases; and Outline strategies for optimizing care coordination for patients with type 2 comorbidities across providers and settings.

Sunandana Chandra, MD, MS - Practical Guidance on Managing Adverse Events Associated With Immunotherapy Regimens for Nonmelanoma Skin Cancers

2024-12-1714:11

Please visit answersincme.com/WJM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses strategies for patient-centered management of immune-related adverse events (AEs) in patients receiving immunotherapy for nonmelanoma skin cancer (NMSC). Upon completion of this activity, participants should be better able to: Identify counseling strategies to educate patients and caregivers about AEs related to immunotherapy regimens for melanoma and NMSC; Describe monitoring schedules for short- and long-term immunotherapy-associated AEs; and Outline multidisciplinary management strategies for immunotherapy-associated AEs in dermatologic malignancies. This activity is intended for US healthcare professionals only.

Erin Barrett (Wei), MD - Focusing on the Patient to Enhance Therapeutic Care: Advancing Early Diagnosis and Management of Bullous Pemphigoid

2024-11-2915:10

Please visit answersincme.com/ZPD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatologic diseases discusses the diagnosis and treatment of bullous pemphigoid. Upon completion of this activity, participants should be better able to: Review the clinical impact of bullous pemphigoid (BP) on patients; Outline diagnostic approaches to enhance the timely identification of patients with BP; and Identify clinical advances that may evolve the therapeutic paradigm for patients with BP.

Nikhil I. Khushalani, MD - Practical Guidance for Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: Using Immunotherapy Effectively in Clinical Practice

2024-11-0615:35

Please visit answersincme.com/JZC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the use of immunotherapy in advanced, unresectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Review current evidence-based recommendations informing the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; Describe the clinical profiles of immunotherapies for the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; and Outline potential considerations to optimize outcomes for patients with unresectable, locally advanced, recurrent, or metastatic CSCC who are on immunotherapies.

Vishal A. Patel, MD - Selecting and Sequencing Systemic Treatment for Advanced Basal Cell Carcinoma

2024-10-2813:42

Please visit answersincme.com/UCA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the management of advanced basal cell carcinoma (BCC) with systemic therapy. Upon completion of this activity, participants should be better able to: Identify patients with BCC who are candidates for a systemic approach to treatment; Review the clinical implications of the evidence on approved and emerging systemic therapies in patients with advanced BCC; and Describe practical strategies to optimize systemic treatment over the long term for patients with advanced BCC. This activity is intended for US healthcare professionals only.

Ahmad Tarhini, MD, PhD - Adjuvant Approaches in High-Risk, Resectable Melanoma: A Practical Guide to Improving Outcomes With Immunotherapy-Based Regimens

2024-09-1914:24

Please visit answersincme.com/RKX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in skin cancer discusses strategies for adjuvant immunotherapy in resectable melanoma. Upon completion of this activity, participants should be better able to: Review the guideline-recommended role of adjuvant immunotherapy for the treatment of resectable melanoma; Describe the key adverse events associated with adjuvant immunotherapy for the treatment of resectable melanoma; Outline evidence-based, patient centric strategies to optimize the benefit-to-risk impact of adjuvant immunotherapy in resectable melanoma care

David M. Miller, MD, PhD / Todd Schlesinger, MD - A Clinician’s Roadmap to Improving Outcomes in Advanced Basal Cell Carcinoma: Guiding Principles for the Use of Immunotherapies

2024-09-1316:17

Please visit answersincme.com/GEU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the management of advanced basal cell carcinoma (BCC) with immunotherapies, based on the guidelines and clinical evidence. Upon completion of this activity, participants should be better able to: Review the guideline recommendations for the treatment of advanced BCC; Identify the clinical implications of the available evidence evaluating immunotherapy options for patients with advanced BCC; and Outline real-world considerations for the integration of immunotherapy into practice for the management of advanced BCC. This activity is intended for US healthcare professionals only.

Vasu Divi, MD, MS - Neoadjuvant Immunotherapy for CSCC: Practical Considerations for Resectability, Patient Selection, and Treatment Optimization

2024-09-0912:35

Please visit answersincme.com/GWE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in head and neck surgery discusses optimizing the in-practice use of neoadjuvant immunotherapy in the treatment of resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe clinical factors that should be considered when evaluating whether a patient with CSCC is a candidate for neoadjuvant immunotherapy; Review the clinical profiles of approved and emerging neoadjuvant immunotherapies for patients with resectable CSCC; and Outline practical considerations to optimize treatment outcomes for patients with resectable CSCC. This activity is intended for US healthcare professionals only.

Vibeke Strand, MD / April W. Armstrong, MD, MPH - A New Take on TYK2 Inhibitors: Bridging Gaps in Psoriatic Arthritis Management With Novel Targeted Therapies

2024-09-0419:56

Please visit answersincme.com/UNV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology, immunology, and rheumatology discuss the management of psoriatic arthritis with novel targeted therapies. Upon completion of this activity, participants should be better able to: Recognize the rationale for novel TYK2 inhibitors in the treatment of psoriatic arthritis; Describe the latest clinical data informing the role of TYK2 inhibitors in the treatment of psoriatic arthritis; and Outline future management considerations for novel TYK2 inhibitors in the treatment of psoriatic arthritis.

Cecelia Damask, DO - Evidence-Based Approaches to Sequencing and Switching Biologic Therapies in Patients With CRSwNP and Comorbidities

2024-08-1618:09

Please visit answersincme.com/VWM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy discusses how to optimize the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbidities with biologic therapies. Upon completion of this activity, participants should be better able to: Identify patients with CRSwNP who are candidates for biologic therapies according to guideline recommendations; Describe best practices for monitoring response to biologic treatment of CRSwNP; and Outline treatment sequencing strategies to optimize the management of CRSwNP. This activity is intended for US healthcare professionals only.

Jonathan Silverberg, MD, PhD, MPH - Taking a Hands-On Approach to the Management of Moderate to Severe Hand and Foot Atopic Dermatitis: Enhancing Patient Outcomes With Novel Systemic Therapies

2024-07-0414:08

Please visit answersincme.com/JPC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses strategies to optimize the management of patients with moderate to severe hand and foot atopic dermatitis (AD), including treatment with novel systemic therapies. Upon completion of this activity, participants should be better able to: Describe the impacts of moderate to severe hand and foot AD on patients’ quality of life; Review the implications of the clinical data for novel systemic therapies in patients with moderate to severe hand and foot AD; and Outline practical, personalized approaches to optimize management of patients with moderate to severe hand and foot AD.

Peter Lio, MD - Generative AI: Benefits for Your Practice, for Your Patients

2024-04-0512:52

Please visit answersincme.com/XGU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses capabilities and potential applications of generative AI in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians’ and patients’ perspectives; and Assess the potential benefits and risks of using generative AI in medical practice.

Peter Lio, MD - AI in Healthcare: A Primer for the Practicing Clinician

2024-04-0514:09

Please visit answersincme.com/WZP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses foundational elements of this emerging technology and its implications in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians’ and patients’ perspectives; and Assess the potential benefits and risks of using generative AI in medical practice.

Nikhil I. Khushalani, MD - Pointing the Way to Enhanced Outcomes in Resectable Cutaneous Squamous Cell Carcinoma: Practical Strategies to Incorporate Neoadjuvant Immunotherapy

2024-02-2618:19

Please visit answersincme.com/GXJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses neoadjuvant immunotherapy in resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; Outline evidence-based, patient-centered strategies to select an appropriate treatment approach for patients with resectable CSCC; and Review strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.

Evan J. Lipson, MD - Real Talk About Maximizing Care in Advanced Melanoma: Balancing Benefit and Risk Using Dual Immunotherapy Regimens

2024-02-1413:24

Please visit answersincme.com/AUY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the role of dual immunotherapeutic approaches to the management of advanced melanoma. Upon completion of this activity, participants should be better able to: Review the clinical goals of patients with advanced melanoma receiving immunotherapy-based treatment; Describe the long-term clinical profiles of dual immunotherapeutic approaches to the management of advanced melanoma; and Outline evidence-based, immunotherapy-focused treatment plans for appropriate patients with advanced melanoma to optimize long-term patient outcomes.

#box-pro-ellipsis-175890688227815{-webkit-line-clamp:2;}CME in Minutes: Education in Dermatology

CME in Minutes: Education in Dermatology